The present study analyzed the clinicopathological and molecular genetic characteristics of 20 Chinese patients with MEITL. In line with the previous studies[12, 13], men were more susceptible than women with a ratio of 2:1. MEITL patients commonly displayed primary symptoms of abdominal pain, accompanied by systemic symptoms such as fever, anemia, and weight loss. Complications such as intestinal perforation are also common. MEITL mostly occurred in the small intestine, but could also inflect the whole GI tract[14]. Previous studies reported colon and stomach as primary sites that also involved mesenteric nodules or other distant organs including liver, spleen, lung, bone, or skin[15, 16]. Skin involvement was rare as it only occurred in 5% of all patients and may present as erythema multiforme skin disease or skin pigmentation[17].
The histological findings and immunohistochemistry of our patients were consistent with those reported in most literature[12, 13, 18, 19], with one exception. The monomorphic and small to medium-sized tumor cells in most cases were positive for CD3, CD8, CD43, CD56, and negative for CD5, with round nuclei, obvious nucleoli, and pale cytoplasm. Increased mitotic activity, frequent necrosis, and epitheliotropic pattern could also be seen. While the outlier case showed cellular pleomorphism and lymph node involvement and had a longer overall survival time after CHOP chemotherapy than other patients. We hypothesized that cellular pleomorphism is related to prognosis, but due to the number of our cohort, the possibility of accidental occurrence cannot be ruled out.
WGS results of nine cases showed the genetic landscape of Chinese population. Mutation-induced abnormal activation of the JAK-STAT pathway together with chromatin remodeling and DNA damage control pathways were pervasive in diverse T cell malignancies and were reported to have an important role in oncogenesis by regulating cell proliferation, survival, differentiation, and immune response[20]. As expected, protein-coding genes involved in the JAK-STAT pathway (STAT5B, JAK3, STAT5A), histone modifiers (SETD2, CREBBP), and DNA damage (TP53) were recurrently mutated. The mutation frequencies of these genes, except SETD2, were similar to those in previous reports[3–5, 21]. SETD2 is an important epigenetic gene encoding histone methyltransferase SETD2 protein which is involved in gene transcription extension and mismatch repair, and the inactivation of SETD2 may contribute to cancer development[22]. SETD2 was found to be the most significant recurrently mutated gene and mutated in up to 60% of patients with MEITL in previous studies reported by Tomita[5], Moffitt[4], and Roberti[3]. But in our study only 2 patients had SETD2 mutations (2/9), showing a lower incidence. Since Tomita’s study was based on Asian patients, we ruled out the interference of ethnic heterogeneity, and we guessed it may be caused by the small sample size and environmental factors.
STAT5B was the most frequently mutated gene in our study. As a member of the STAT family, STAT5B plays a key regulatory role in the pathogenesis of various disease drivers, including BCR/ABL[23] and NPM-ALK[24], and expresses at a high level in hematological malignancies[25]. There have revealed multiple mutation hot-spots within SH2 and C-terminal domains in STAT5B, among which N642H has been discovered in various hematological malignancies of T cell origin including T-cell acute lymphoblastic leukemia(T-ALL), T-cell prolymphocytic leukemia(T-PLL), and MEITL[26]. Patient with a STAT5B N642H variant has a risk of relapse, drug resistance and poor outcome[27]. N642H was detected in two of four STAT5B-mutated cases in our study and predicted to be probably damaging by Polyphen-2. Two novel variants Y665F and A776V had also been found, but needed more research to explore their functions.
Our study showed for the first time frequent ZDBF2 mutations. ZDBF2 is located on chromosome 2q33.3 and encodes a protein containing DBF4-type zinc finger domains, related to nucleic acid binding and zinc ion binding according to GO annotations[28]. So far, only Nasopalpebral Lipoma-Coloboma Syndrome[28] and Temple Syndrome[29], both of which are dominant genetic diseases, have been reported to be associated with ZDBF2. Since frequent frameshift mutation K1726Nfs*5(rs745875253) was discovered in our study and ZDBF2 was reported to be imprinted and paternally expressed in lymphocytes[30], we speculate that ZDBF2 is an important gene contributing to the MEITL mechanism and had been largely overlooked.
Abnormalities of Chr9q were frequently detected in non-Hodgkin lymphoma, especially loss of Chr9q[31]. Both Type-I EATL and MEITL were characterized by Chr9q gains[32], and its frequency could be up to 75% in MEITL[3, 33]. Our research had verified that amplification of Chr9q(7/9) was the most common chromosome copy number variant in MEITL, and multiple important oncogenes on Chr9q showed consistent amplifications. Five cases also had mutations of JAK-STAT pathway-related genes at the same time. Though recurrent Chr9q gains were reported in mantle cell lymphoma(MCL), its frequency was lower, and the characteristic mutated genes in MCL were not related to the JAK-STAT pathway. These findings indicated that a combination of genetic mutations and Chr9q gains could be used as one of the molecular features of MEITL diagnosis.
There were some limitations in the current research. First, due to the small sample size, we have not yet analyzed the correlation between the genetic changes and clinicopathological manifestations. Second, the pathogenic mechanisms of the above genetic changes on MEITL have not been further studied. We will continue to collect Chinese MEITL cases to solve the above problems and verify our results.